Drew Hopper.

AIRPORT CITY, Israel—NovaSight, a pediatric-focused eyecare company, announced a pair of major year-end developments. CureSight, NovaSight’s innovative digital therapy for amblyopia (lazy eye), will be released to the U.S. market beginning this month, while Drew Hopper has been appointed to vice president of sales and marketing North America, an instrumental position in the rollout of the device. Hopper, an accomplished global commercial executive leader with more than 20 years of experience in sales and marketing—including a decade in the eyecare space—said he is eager to help NovaSight get this technology into the hands of U.S. eyecare practitioners and their patients.

In his new role, Hopper will build relationships with clients, recruit key opinion leaders (KOLs) to serve on NovaSight’s scientific advisory board; support the company’s reimbursement efforts through discussions with payers, and develop, manage, and maintain consistent and effective sales and marketing initiatives.

CureSight received U.S. Food and Drug Administration (FDA) 510(K) clearance based on a pivotal study that found the device to be non-inferior to eye patching—the current gold standard of care—for amblyopia treatment in children. CureSight therapy is carried out while the child watches any streamed content of their choice on a user-friendly, eye tracking based device from the comfort of their home. Treatment reports are shared via a web portal allowing eyecare providers to monitor patient treatment progress and compliance. “We are thrilled to have the opportunity to introduce CureSight to U.S. eyecare providers and their patients, and truly gratified to have Drew Hopper on board to guide the campaign,” said Ran Yam, NovaSight co-founder and CEO.

“We are excited to bring CureSight into the U.S. market, and to begin the process of building out our U.S. based commercial capabilities,” added Hopper. A Physician Early Adopter’s Program, a dedicated CureSight Monitoring Center, and three unique CPT codes will assist U.S. eyecare providers in integrating CureSight into their practices.”

Select participants in the Physician’s Early Adopter Program will begin referring CureSight to their amblyopic patients starting this month, according to the company. The next step of the U.S. commercialization will commence during the first half of 2023 with an official launch that will include a group of hundreds of physicians who have already signed up to the CureSight Referral Program.